New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:59 EDTZGNX, ESRXZogenix price target lowered to $2.50 from $5 at Oppenheimer
Oppenheimer cut its price target on Zogenix (ZGNX) after coverage of the company's Zohydro painkiller was terminated by Express Scripts (ESRX). However, the firm thinks recent disappointing news about Zogenix is already reflected in the stock. Oppenheimer keeps an Outperform rating on the shares.
News For ZGNX;ESRX From The Last 14 Days
Check below for free stories on ZGNX;ESRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
16:27 EDTZGNXZogenix gets exclusive licensing for Zohydro ER from Daravita
Subscribe for More Information
08:40 EDTZGNXZogenix reports new data shows Zohydro ER reduced pain, improved function
Subscribe for More Information
September 11, 2014
10:00 EDTESRXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:30 EDTESRXExpress Scripts downgraded to Neutral from Buy at Goldman
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use